Floatz logo

Tnhyp217 Car T Cells

Colonic Neoplasms

National Cancer Institute (NCI)Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Colonic Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
First Affiliated Hospital of Guangxi Medical University
Phase 4BBB
Ertapenem
University of Ulm
Phase 4BB
PROPOFOL
Hillel Yaffe Medical Center
Phase 4BB
Levoleucovorin
Asan Medical Center
Phase 2BB
Sevoflurane
Uppsala University
Phase 4BB

View all 50 →

Same molecule, other indications

Tnhyp217 Car T Cells is also rated in:

thymus neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
gastric neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
mesotheliomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →